NCT01379287View on ClinicalTrials.gov

Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

June 20, 2011

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions

Solid Tumors

Interventions

DRUG

Iso-Fludelone

Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

University of Pittsburgh

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01379287 - Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter